1. Primary endpoint at 1 year
I-LOVE-IT 2
Trial design: Chinese patients with CAD undergoing PCI were randomized in a 2:1 fashion to receive either biodegradable (PLGA) polymer-coated SES (BP-SES) or durable polymer-coated SES (DP-SES). Patients were followed for 1 year.
Results
(p = )*
Primary endpoint: target lesion failure for BP-SES vs. DP-SES: 6.3% vs. 6.1%, pnoninferiority =
Cardiac death: 0.7% vs. 0.6%, p = 0.62; target vessel MI: 3.6% vs. 4.3%, p = 0.39; TLR: 2.6% vs. 2.2%, p = 0.5; definite/probable stent thrombosis: 0.4% vs. 0.6%, p = 0.55 %
Conclusions
BP-SES is noninferior to DP-SES for clinical outcomes including stent thrombosis at 1 year in patients undergoing PCI
DP-SES is not the same as Cypher® SES, which was on a stainless steel platform; this trial adds to the literature on bioresorbable stents
Longer-term follow-up data are awaited
Primary endpoint at 1 year
* For noninferiority
BP-SES
(n = 1,829)
DP-SES
(n = 908)
Han Y, et al. JACC Cardiovasc Interv 2014;Sep 16:[Epub]